Submissions for variant NM_007294.3(BRCA1):c.4484G>C (p.Arg1495Thr) (rs80357389)

Total submissions: 3

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000236135	SCV000292747	pathogenic	not provided	2015-10-29	criteria provided, single submitter	clinical testing	This variant is denoted BRCA1 c.4484G>C at the cDNA level, p.Arg1495Thr (R1495T) at the protein level, and results in the change of an Arginine to a Threonine (AGG>ACG). Using alternate nomenclature, this variant would be defined as BRCA1 4603G>C. This variant was observed in an mRNA in-vitro splicing assay to create two aberrant transcripts, both of which lead to deleterious protein function, one skipping exon 14 and the other skipping exons 14-15 (Whiley 2014). BRCA1 Arg1495Thr was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Arginine and Threonine differ in some properties, this is considered a semi-conservative amino acid substitution. BRCA1 Arg1495Thr occurs at a position that is not conserved and is located within the SCD domain, the DNA binding domain and within a region known to interact with multiple other proteins (Narod 2004, Paul 2014). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on the currently available information, we consider BRCA1 Arg1495Thr to be a pathogenic variant.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000258262	SCV000325978	pathogenic	Breast-ovarian cancer, familial 1	2015-10-02	criteria provided, single submitter	clinical testing
Color	RCV000580649	SCV000683188	pathogenic	Hereditary cancer-predisposing syndrome	2015-11-19	criteria provided, single submitter	clinical testing